| 21.0593 -0.251 (-1.18%) | 06-29 10:04 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 25.05  |
1-year : | 29.26 |
| Resists | First : | 21.45 |
Second : | 25.05 |
| Pivot price | 18.97 |
|||
| Supports | First : | 18.48 |
Second : | 16.65 |
| MAs | MA(5) : | 20.36 |
MA(20) : | 18.77 |
| MA(100) : | 21.33  |
MA(250) : | 18.18 |
|
| MACD | MACD : | 0.1 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 89.8 |
D(3) : | 85.2 |
| RSI | RSI(14): 65.1 |
|||
| 52-week | High : | 25.59 | Low : | 8.58 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ SNDX ] has closed below upper band by 5.7%. Bollinger Bands are 48.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 21.38 - 21.47 | 21.47 - 21.54 |
| Low: | 19.7 - 19.8 | 19.8 - 19.88 |
| Close: | 21.13 - 21.3 | 21.3 - 21.45 |
Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing innovative therapies for cancer. Among its leading investigational products are SNDX-5613, currently undergoing Phase 1/2 clinical assessment, which targets the Menin-mixed lineage leukemia 1 protein interaction for treating MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML). Another significant candidate is SNDX-6352, or axatilimab, a monoclonal antibody designed to block the colony stimulating factor 1 (CSF-1) receptor, intended for patients suffering from chronic graft versus host disease (cGVHD). The company is additionally progressing Entinostat. Syndax has also established strategic collaborations, including a research and development agreement with the National Cancer Institute, a clinical trial agreement with the Eastern Cooperative Oncology Group, and a license agreement with Kyowa Hakko Kirin Co., Ltd. Founded in 2005, Syndax Pharmaceuticals, Inc. maintains its corporate headquarters in Waltham, Massachusetts.
Mon, 29 Jun 2026
Syndax Pharmaceuticals, Inc.(NasdaqGS:SNDX) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Mon, 29 Jun 2026
Enterprise value to revenue forward of Syndax Pharmaceuticals, Inc. – NASDAQ:SNDX - TradingView
Mon, 29 Jun 2026
Syndax Pharmaceuticals, Inc.(NasdaqGS:SNDX) dropped from Russell 3000 Value Benchmark - marketscreener.com
Sun, 28 Jun 2026
Does Syndax Pharmaceuticals’ (SNDX) Russell Value Index Exit Quietly Recast Its Liquidity And Risk Narrative? - simplywall.st
Tue, 23 Jun 2026
Syndax Pharmaceuticals (SNDX) Stock Could Be 51.9% Undervalued After SAVE Trial Data - Sahm
Sat, 20 Jun 2026
Syndax Pharmaceuticals (SNDX) TD Cowen 46th Annual Health Care Conference Summary - Quartr
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 89 (M) |
| Shares Float | 80 (M) |
| Held by Insiders | 1.7 (%) |
| Held by Institutions | 116 (%) |
| Shares Short | 19,860 (K) |
| Shares Short P.Month | 21,710 (K) |
| EPS | -2.79 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.46 |
| Profit Margin | -112.1 % |
| Operating Margin | -52.8 % |
| Return on Assets (ttm) | -25.2 % |
| Return on Equity (ttm) | -189.6 % |
| Qtrly Rev. Growth | 223.6 % |
| Gross Profit (p.s.) | -0.57 |
| Sales Per Share | 2.45 |
| EBITDA (p.s.) | -2.53 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -278 (M) |
| Levered Free Cash Flow | -186 (M) |
| PE Ratio | -7.57 |
| PEG Ratio | 0 |
| Price to Book value | 44.93 |
| Price to Sales | 8.61 |
| Price to Cash Flow | -6.73 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|